Evaxion announces business update and second quarter 2023 financial results

Promising clinical data from phase 1 and 2a studies with evx-01 and evx-02 were presented at aacr and asco in q2 2023 a novel proprietary genetic vaccine adjuvant was presented at evaxion's r&d day in may. the technology is an integral part of the next-generation cancer vaccine, evx-03, planned for phase 1 clinical trial application in q4 2023* promising results on evx-b1, a staphylococcus aureus vaccine candidate, were presented at the staphylococcal diseases gordon research conference in new hampshire, usa, in q2 2023.
EVAX Ratings Summary
EVAX Quant Ranking